Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novartis Pharma
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A single center, phase I, partially blinded, placebo-controlled, first-in-man study to evaluate the safety, tolerability and Proof of Mechanism (PoM) of a single administration of BFH772 in healthy volunteers, and Proof of Concept (PoC) study to evaluate the safety, tolerability, and pharmacodynamics of multiple topical administrations of BFH772 in patients with psoriasis
• Investigate the safety and tolerability of single and multiple doses of BFH772 in two different formulations in healthy and psoriatic subjects • Assess the efficacy of topically applied BFH772 to tr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
An open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy (PDR)
To assess the long-term safety and tolerability of open-label treatment with Sandostatin LAR 30 mg in patients who completed the double-masked study CSMS995 0802
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
An open-label, multi-center trial to evaluate the feasibility and safety of short-term treatment with subcutaneously injected certoparin (8000 U anti-Xa twice daily) in patients with persistent nonvalvular atrial fibrillation
Primary objective is to document the feasibility and safety of short-term treatment with a fixed, body weight-independent certoparin regimen (8000 U anti-Xa twice daily) in patients with persistent no...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A 16-day, randomized, double-blind, double-dummy, placebo-controlled, parallel-group trial comparing lumiracoxib 100mg o.d. with naproxen 500 mg b.i.d. plus omeprazole 20mg o.d. and placebo in healthy volunteers to confirm the safety and tolerability of lumiracoxib in the small bowel
The primary objective of this study is to demonstrate, by video capsule endoscopy (VCE), that the percentage of subjects with one or more small bowel mucosal breaks (with or without hemorrhage) is si...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Safety & Efficacy of BCT197A2201 in COPD patients presenting with an exacerbation
• To assess the efficacy of a single and repeated dose of BCT197 in COPD patients presenting with an exacerbation measured by the improvement in FEV1 over the first 5 days of treatment relative to pla...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
The study will evaluate the effects of BHQ880 in patients with previously untreated multiple myeloma and renal insufficiency who are not considered candidates for bisphosphonate therapy
Assess the effect of BHQ880 compared with placebo on time to first SRE in patients with untreated multiple myeloma and renal insufficiency in combination with bortezomib and dexamethasone
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A randomized, double-blind, placebo controlled, withdrawal study of flare prevention of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations
Part II: to demonstrate that the time to flare in Part II is higher with canakinumab than with placebo. Part I: to assess if canakinumab allows tapering of steroids as per protocol in at least 25% of ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A multi-centre, randomized, double-blind, placebo-controlled, two-period, crossover proof-of-concept study in patients with Fragile X Syndrome to assess the efficacy, safety and tolerability of multiple oral doses of AFQ056
- To assess the efficacy of multiple oral doses of AFQ056 in reducing the global score of the Aberrant Behavior Checklist – Community Edition (ABC-C) in FXS patients. - To assess the safety and tolera...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Glivec (imatinib mesylate) in combination with hydroxyurea or hydroxyurea alone as an oral therapy in temozolomide resistant progressive glioblastoma patients
The main objective of the study is to show that the combination of imatinib mesylate (GLIVEC) and hydroxyurea is superior to hydroxyurea alone in prolonging progression free survival (PFS) of patients...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme
Entre 12 ans
et 99 ans
Novartis Pharma
MAJ Il y a 5 ans
Étude CLTT462X2101 : Etude de phase 1 évaluant la sécurité et la tolérance du LTT462 chez des patients ayant des tumeurs solides à un stade avancé avec altérations de la voie MAPK. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Une tumeur solide est une grosseur plus ou moins volumineuse due à une multiplication excessive de cellules, cancéreuses ou non. Les tumeurs solides cancéreuses, comme les carcinomes ou les sarcomes, ...
Pays
France
Organes
Ovaire
,
Poumon, type à petites cellules
,
Mélanomes cutanés
,
Tumeurs solides
Spécialités
Thérapies Ciblées
Essai clos aux inclusions
Plus d'informations
Précédent
23
24
25
26
27
28
29
30
31
32
Suivant